Company achieved key clinical milestones with successful completion of Cohort 1 follow-up and full enrollment of Cohort 2, demonstrating clinical efficacy and safety. Positive FDA interactions support advancement to pivotal trial. Strong cash position of $180 million provides runway for development. Interim results accepted for presentation at major conference indicate scientific validation.
Also mentions BNTC
Articles that tag BNTC but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
